Univariate and multivariate analysis of factors associated with survival following progression after CD19 CAR T-cell therapy
| . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| Parameter . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Age (>40 vs ≤40 y) | 1.64 (0.80-3.34) | .20 | — | — |
| Sex (male vs female) | 0.53 (0.21-1.34) | .20 | — | — |
| Philadelphia chromosome–positive ALL (yes vs no) | 0.63 (0.29-1.35) | .20 | — | — |
| History of prior HSCT before CAR T cells (yes vs no) | 0.63 (0.30-1.30) | .20 | — | — |
| Prior blinatumomab or inotuzumab before CAR T cells (yes vs no) | 1.78 (0.79-4.0) | .20 | — | — |
| Bridging therapy before CAR T-cell infusion (no or nonintensive vs intensive) | 0.36 (0.16-0.83) | .02 | 0.41 (0.14-1.16) | .09 |
| Time from CAR T-cell infusion to relapse in months | 0.94 (0.86-1.02) | .09 | 0.91 (0.83-1.00) | .04 |
| BM blasts at the time of relapse | 1.01 (1.00-1.03) | .08 | 1.01 (0.99-1.03) | .2 |
| Extramedullary relapse (yes vs no) | 0.85 (0.4-1.82) | .70 | — | — |
| CD19 expression at relapse (positive vs negative) | 0.63 (0.22-1.76) | .40 | — | — |
| Salvage therapy after relapse (yes vs no) | 0.48 (0.17-1.35) | .16 | — | — |
| Blinatumomab or inotuzumab as salvage therapy after relapse (yes vs no) | 1.41 (0.60-3.33) | .43 | — | — |
| . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| Parameter . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Age (>40 vs ≤40 y) | 1.64 (0.80-3.34) | .20 | — | — |
| Sex (male vs female) | 0.53 (0.21-1.34) | .20 | — | — |
| Philadelphia chromosome–positive ALL (yes vs no) | 0.63 (0.29-1.35) | .20 | — | — |
| History of prior HSCT before CAR T cells (yes vs no) | 0.63 (0.30-1.30) | .20 | — | — |
| Prior blinatumomab or inotuzumab before CAR T cells (yes vs no) | 1.78 (0.79-4.0) | .20 | — | — |
| Bridging therapy before CAR T-cell infusion (no or nonintensive vs intensive) | 0.36 (0.16-0.83) | .02 | 0.41 (0.14-1.16) | .09 |
| Time from CAR T-cell infusion to relapse in months | 0.94 (0.86-1.02) | .09 | 0.91 (0.83-1.00) | .04 |
| BM blasts at the time of relapse | 1.01 (1.00-1.03) | .08 | 1.01 (0.99-1.03) | .2 |
| Extramedullary relapse (yes vs no) | 0.85 (0.4-1.82) | .70 | — | — |
| CD19 expression at relapse (positive vs negative) | 0.63 (0.22-1.76) | .40 | — | — |
| Salvage therapy after relapse (yes vs no) | 0.48 (0.17-1.35) | .16 | — | — |
| Blinatumomab or inotuzumab as salvage therapy after relapse (yes vs no) | 1.41 (0.60-3.33) | .43 | — | — |
Factors with values of P ≤ .1 in univariate analysis were included in multivariate analysis.